1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
39
Fırat Tıp
Dergis
i 2011;16(1): 38-40
Yokuş
v
e Ark.
5. Kralovics R, Passamonti F, Buser AS, et all. A gain of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med
2005; 350: 1779-1790.
6. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006; 240-245.
7. Michiels JJ, Berneman Z, Van Bockstaele D. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006; 32: 174¬207.
8. Mosso M, Georgiadis D, Baumgartner RW. Progressive occlusive disease of large cerebral arteries and ischemic events in a patient with essential thrombocythemia. Neurol Res 2004;
26: 702-703.
9. Bellucci S, Michiels JJ. The role of JAK2 V617F mutation,
spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006; 32: 381-398.
10. Bellanne-Chantelot C, Chaumarel I, Labopin M, France. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108:
346-352.
11. Toyama K, Karasawa M, Yamane A et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Br J Haematol 2007; 139: 64-69.
12. Hirayama Y, Sakamaki S, Matsunaga T, et al. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. Blood 1998; 92: 46-52.
13. Barth A. Carotid stenosis: diagnosis, patient selection, therapy. Ther Umsch 2003; 60: 563-568.
14. van der Vaart MG, Meerwaldt R, Reijnen MM. Endarterectomy or carotid artery stenting: the quest continues. Am J Surg 2008;
195: 259-269.
15. Kurabayashi H, Hishinuma A, Uchida R. Delayed manifestation and slow progression of cerebral infarction caused by
polycythemia rubra vera. Am J Med Sci 2007; 333: 317-320.
16. Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol 2002; 9: 16-21.
17. Cucuianu A, Stoia M, Farcaş A, Dima D, Zdrenghea M. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia. Rom J Intern Med 2006; 44: 397-406.
18. Friedman KD, Rodgers GM. Thrombosis and Antithrombotic Therapy. In: Greer JP, Foerster J, Lukens J, Rodgers G, Paraskevas F, Glader B (Editors). Wintrobe's Clinical Hematology. 11. Baskı, Philadelphia: Lippincott Williams&
Wilkins, 2004: 1713-1728.
Thank you for copying data from http://www.arastirmax.com